Zydus Lifesciences Limited Share Price & Analysis
₹1,090.5Updated 5 Jun 2026, 03:30 pm IST
LTP
₹1,090.5
—
Open
₹1,085.1
High
₹1,097
Low
₹1,082.2
Close
₹1,084.6
52W High
₹1,116
52W Low
₹836
Volume
919K
Lot Size
900
Sector
Healthcare
Market Cap
₹1.1L Cr
Face Value
₹1
Large CapNIFTY 100NIFTY 200NIFTY 500NEXT 50
Price Chart
Fundamentals
P/E
20
Sector P/E
48.9
P/B
4.05
EPS
₹49.09
ROE
21.2%
ROCE
21.2%
D/E Ratio
0.46
Div Yield
0.09%
Book Value
₹269
+
Strengths
- ✓Excellent return on equity (ROE 21.2%)
- ✓Efficient capital deployment (ROCE 21.2%)
- ✓Attractively valued vs sector (P/E 20x vs industry 48.9x)
- ✓Low debt relative to equity (D/E 0.5x)
−
Concerns
- ✗Trading near 52-week high (₹1,116)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
| LUPIN Lupin Limited | ₹2,260 | ₹1.0L Cr | 17.9 | 4.6 | 29.1 | 30.3 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ZYDUSLIFE · as of Mar 2026
Promoters75.00%▲0.02
FII7.31%▼0.22
DII10.95%▲0.34
Public6.69%▼0.16
Govt0.05%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 74.98% | 74.98% | 74.98% | 74.98% | 74.98% | 75.00% |
| FII | 4.99% | 5.72% | 5.59% | 7.52% | 7.53% | 7.31% |
| DII | 12.96% | 12.55% | 12.56% | 10.59% | 10.61% | 10.95% |
| Public | 6.99% | 6.66% | 6.81% | 6.85% | 6.85% | 6.69% |
| Govt | 0.07% | 0.07% | 0.07% | 0.05% | 0.05% | 0.05% |
Corporate Events
Dividend - Re 1 Per Share
Dividend23 Jul 2026
Buy Back
Buy Back28 May 2026
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend18 May 2026
To consider buyback for equity shares
Buy Back18 May 2026
Dividend - Rs 11 Per Share
Dividend24 Jul 2025
Dividend - Rs 3 Per Share
Dividend25 Jul 2024
Buy Back
Buy Back22 Feb 2024
Dividend - Rs 6 Per Share
Dividend27 Jul 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6.9K Cr ▲12.1% | ₹6.1K Cr ▼6.9% | ₹6.6K Cr ▲0.7% | ₹6.5K Cr ▲23.9% | ₹5.3K Cr ▲0.6% | ₹5.2K Cr ▼15.6% | ₹6.2K Cr ▲12.2% | ₹5.5K Cr |
| Op. Profit | ₹1.8K Cr ▼9.9% | ₹2.0K Cr ▼3.4% | ₹2.1K Cr ▼1.8% | ₹2.1K Cr ▲53.2% | ₹1.4K Cr ▼5.0% | ₹1.5K Cr ▼29.9% | ₹2.1K Cr ▲27.9% | ₹1.6K Cr |
| OPM | 26.0% ▼21.2% | 33.0% ▲3.1% | 32.0% ▼3.0% | 33.0% ▲26.9% | 26.0% ▼7.1% | 28.0% ▼17.6% | 34.0% ▲17.2% | 29.0% |
| Net Profit | ₹1.0K Cr ▼17.4% | ₹1.2K Cr ▼18.5% | ₹1.5K Cr ▲22.3% | ₹1.2K Cr ▲21.2% | ₹1.0K Cr ▲11.5% | ₹920 Cr ▼37.9% | ₹1.5K Cr ▲18.9% | ₹1.2K Cr |
| EPS (₹) | 10.36 ▼17.2% | 12.51 ▼14.2% | 14.58 ▲25.3% | 11.64 ▲14.5% | 10.17 ▲12.3% | 9.06 ▼35.8% | 14.11 ▲20.1% | 11.75 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹27.1K Cr ▲16.8% | ₹23.2K Cr ▲18.9% | ₹19.5K Cr ▲13.4% | ₹17.2K Cr ▲12.9% | ₹15.3K Cr ▲1.1% | ₹15.1K Cr ▲6.0% | ₹14.3K Cr ▲8.3% | ₹13.2K Cr ▲10.6% | ₹11.9K Cr ▲27.0% | ₹9.4K Cr |
| Expenses | ₹18.7K Cr ▲15.4% | ₹16.2K Cr ▲14.3% | ₹14.2K Cr ▲5.9% | ₹13.4K Cr ▲12.2% | ₹11.9K Cr ▲1.4% | ₹11.8K Cr ▲2.6% | ₹11.5K Cr ▲12.6% | ₹10.2K Cr ▲12.1% | ₹9.1K Cr ▲21.4% | ₹7.5K Cr |
| Op. Profit | ₹8.5K Cr ▲20.1% | ₹7.1K Cr ▲31.1% | ₹5.4K Cr ▲39.5% | ₹3.9K Cr ▲15.5% | ₹3.3K Cr ▼0.1% | ₹3.3K Cr ▲19.5% | ₹2.8K Cr ▼6.5% | ₹3.0K Cr ▲5.7% | ₹2.8K Cr ▲48.8% | ₹1.9K Cr |
| OPM | 31.0% ▲3.3% | 30.0% ▲7.1% | 28.0% ▲27.3% | 22.0% ▲0.0% | 22.0% ▲0.0% | 22.0% ▲10.0% | 20.0% ▼13.0% | 23.0% ▼4.2% | 24.0% ▲20.0% | 20.0% |
| Other Income | ₹-7 Cr ▼114.0% | ₹50 Cr ▼82.9% | ₹293 Cr ▲169.4% | ₹-422 Cr ▼116.4% | ₹2.6K Cr ▲1609.4% | ₹-171 Cr ▲35.2% | ₹-264 Cr ▼244.3% | ₹183 Cr ▲64.9% | ₹111 Cr ▼12.6% | ₹127 Cr |
| Interest | ₹439 Cr ▲164.5% | ₹166 Cr ▲104.9% | ₹81 Cr ▼37.7% | ₹130 Cr ▲2.4% | ₹127 Cr ▼22.6% | ₹164 Cr ▼52.0% | ₹342 Cr ▲76.3% | ₹194 Cr ▲113.2% | ₹91 Cr ▲102.2% | ₹45 Cr |
| Depreciation | ₹1.4K Cr ▲53.7% | ₹916 Cr ▲19.9% | ₹764 Cr ▲5.7% | ₹723 Cr ▲1.4% | ₹713 Cr ▼1.7% | ₹725 Cr ▲4.2% | ₹696 Cr ▲16.2% | ₹599 Cr ▲11.1% | ₹539 Cr ▲44.5% | ₹373 Cr |
| PBT | ₹6.6K Cr ▲9.9% | ₹6.0K Cr ▲24.7% | ₹4.8K Cr ▲86.9% | ₹2.6K Cr ▼49.2% | ₹5.1K Cr ▲122.5% | ₹2.3K Cr ▲52.8% | ₹1.5K Cr ▼37.2% | ₹2.4K Cr ▲3.0% | ₹2.3K Cr ▲43.4% | ₹1.6K Cr |
| Tax % | 24.0% ▲4.3% | 23.0% ▲15.0% | 20.0% ▼13.0% | 23.0% ▲130.0% | 10.0% ▲66.7% | 6.0% ▼71.4% | 21.0% ▼4.5% | 22.0% ▼8.3% | 24.0% ▲200.0% | 8.0% |
| Net Profit | ₹5.1K Cr ▲9.7% | ₹4.7K Cr ▲17.6% | ₹4.0K Cr ▲89.9% | ₹2.1K Cr ▼54.7% | ₹4.6K Cr ▲111.4% | ₹2.2K Cr ▲81.5% | ₹1.2K Cr ▼36.6% | ₹1.9K Cr ▲4.9% | ₹1.8K Cr ▲19.3% | ₹1.5K Cr |
| EPS (₹) | 50.09 ▲11.4% | 44.97 ▲17.2% | 38.36 ▲98.0% | 19.37 ▼55.8% | 43.83 ▲110.3% | 20.84 ▲81.4% | 11.49 ▼36.4% | 18.06 ▲4.1% | 17.35 ▲19.4% | 14.53 |
| Div Payout | 2.0% ▼91.7% | 24.0% ▲200.0% | 8.0% ▼74.2% | 31.0% ▲416.7% | 6.0% ▼64.7% | 17.0% ▼43.3% | 30.0% ▲57.9% | 19.0% ▼5.0% | 20.0% ▼9.1% | 22.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹101 Cr ▲0.0% | ₹101 Cr ▲0.0% | ₹101 Cr ▲0.0% | ₹101 Cr ▼1.0% | ₹102 Cr ▲0.0% | ₹102 Cr ▲0.0% | ₹102 Cr ▲0.0% | ₹102 Cr ▲0.0% | ₹102 Cr ▲0.0% | ₹102 Cr |
| Reserves | ₹25.2K Cr ▲5.7% | ₹23.9K Cr ▲20.9% | ₹19.7K Cr ▲13.3% | ₹17.4K Cr ▲3.1% | ₹16.9K Cr ▲31.1% | ₹12.9K Cr ▲25.5% | ₹10.3K Cr ▼0.1% | ₹10.3K Cr ▲19.0% | ₹8.6K Cr ▲26.0% | ₹6.9K Cr |
| Borrowings | ₹9.6K Cr ▲199.9% | ₹3.2K Cr ▲299.6% | ₹804 Cr ▼32.7% | ₹1.2K Cr ▼71.7% | ₹4.2K Cr ▼7.9% | ₹4.6K Cr ▼42.6% | ₹8.0K Cr ▲1.1% | ₹7.9K Cr ▲46.1% | ₹5.4K Cr ▲3.8% | ₹5.2K Cr |
| Other Liabilities | ₹12.0K Cr ▲25.6% | ₹9.5K Cr ▲16.1% | ₹8.2K Cr ▲19.7% | ₹6.9K Cr ▲6.7% | ₹6.4K Cr ▲3.7% | ₹6.2K Cr ▲21.0% | ₹5.1K Cr ▲3.4% | ₹4.9K Cr ▲36.2% | ₹3.6K Cr ▲23.7% | ₹2.9K Cr |
| Total Liabilities | ₹46.9K Cr ▲27.8% | ₹36.7K Cr ▲27.2% | ₹28.8K Cr ▲12.8% | ₹25.6K Cr ▼7.5% | ₹27.6K Cr ▲16.3% | ₹23.8K Cr ▲1.2% | ₹23.5K Cr ▲1.1% | ₹23.2K Cr ▲30.6% | ₹17.8K Cr ▲17.7% | ₹15.1K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹23.1K Cr ▲75.6% | ₹13.1K Cr ▲6.2% | ₹12.4K Cr ▲7.4% | ₹11.5K Cr ▼6.0% | ₹12.3K Cr ▲1.0% | ₹12.1K Cr ▼0.8% | ₹12.2K Cr ▲0.5% | ₹12.2K Cr ▲87.6% | ₹6.5K Cr ▲12.6% | ₹5.8K Cr |
| CWIP | ₹1.2K Cr ▼55.8% | ₹2.7K Cr ▲11.1% | ₹2.4K Cr ▲101.7% | ₹1.2K Cr ▲81.7% | ₹661 Cr ▼15.6% | ₹783 Cr ▲5.5% | ₹742 Cr ▼11.4% | ₹837 Cr ▼45.2% | ₹1.5K Cr ▼1.0% | ₹1.5K Cr |
| Investments | ₹5.9K Cr ▼8.3% | ₹6.4K Cr ▲425.2% | ₹1.2K Cr ▼21.1% | ₹1.5K Cr ▼53.0% | ₹3.3K Cr ▲296.1% | ₹830 Cr ▲8.5% | ₹765 Cr ▲13.5% | ₹674 Cr ▼9.7% | ₹746 Cr ▲71.5% | ₹435 Cr |
| Other Assets | ₹16.8K Cr ▲16.0% | ₹14.5K Cr ▲12.7% | ₹12.8K Cr ▲13.5% | ₹11.3K Cr ▼1.3% | ₹11.4K Cr ▲14.2% | ₹10.0K Cr ▲2.9% | ₹9.7K Cr ▲1.9% | ₹9.6K Cr ▲5.8% | ₹9.0K Cr ▲22.5% | ₹7.4K Cr |
| Total Assets | ₹46.9K Cr ▲27.8% | ₹36.7K Cr ▲27.2% | ₹28.8K Cr ▲12.8% | ₹25.6K Cr ▼7.5% | ₹27.6K Cr ▲16.3% | ₹23.8K Cr ▲1.2% | ₹23.5K Cr ▲1.1% | ₹23.2K Cr ▲30.6% | ₹17.8K Cr ▲17.7% | ₹15.1K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹6.8K Cr ▲109.9% | ₹3.2K Cr ▲20.0% | ₹2.7K Cr ▲27.8% | ₹2.1K Cr ▼36.1% | ₹3.3K Cr ▲31.5% | ₹2.5K Cr ▲95.4% | ₹1.3K Cr ▲39.5% | ₹919 Cr ▼30.0% | ₹1.3K Cr ▼30.7% | ₹1.9K Cr |
| Investing CF | ₹-8.4K Cr ▼461.5% | ₹-1.5K Cr ▼226.7% | ₹1.2K Cr ▲3.6% | ₹1.1K Cr ▲236.2% | ₹-835 Cr ▲17.5% | ₹-1.0K Cr ▲74.6% | ₹-4.0K Cr ▼308.3% | ₹-974 Cr ▲66.1% | ₹-2.9K Cr ▼234.0% | ₹-860 Cr |
| Financing CF | ₹2.0K Cr ▲211.3% | ₹-1.8K Cr ▲58.9% | ₹-4.4K Cr ▼406.9% | ₹-868 Cr ▲65.9% | ₹-2.5K Cr ▼133.0% | ₹-1.1K Cr ▼158.0% | ₹1.9K Cr ▲3525.0% | ₹52 Cr ▼97.8% | ₹2.3K Cr ▲347.7% | ₹-935 Cr |
| Net Cash Flow | ₹414 Cr ▲652.0% | ₹-75 Cr ▲86.0% | ₹-534 Cr ▼122.5% | ₹2.4K Cr ▲2736.7% | ₹-90 Cr ▼122.6% | ₹399 Cr ▲149.2% | ₹-811 Cr ▼26933.3% | ₹-3 Cr ▼100.4% | ₹756 Cr ▲663.6% | ₹99 Cr |
| Free Cash Flow | ₹5.1K Cr ▲118.2% | ₹2.3K Cr ▲38.2% | ₹1.7K Cr ▲61.6% | ₹1.1K Cr ▼57.1% | ₹2.4K Cr ▲51.3% | ₹1.6K Cr ▲585.2% | ₹236 Cr ▲303.4% | ₹-116 Cr ▲92.9% | ₹-1.6K Cr ▼273.4% | ₹936 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 63d ▼35.1% | 97d ▲3.2% | 94d ▲17.5% | 80d ▲5.3% | 76d ▼19.1% | 94d ▼14.5% | 110d ▲12.2% | 98d ▲10.1% | 89d ▲30.9% | 68d |
| Inventory Days | 227d ▲12.4% | 202d ▲2.5% | 197d ▼19.6% | 245d ▲7.9% | 227d ▲9.7% | 207d ▼0.5% | 208d ▼1.4% | 211d ▲9.3% | 193d ▲22.2% | 158d |
| Days Payable | 133d ▲6.4% | 125d ▲1.6% | 123d ▼12.8% | 141d ▼9.0% | 155d ▲2.6% | 151d ▲1.3% | 149d ▼10.8% | 167d ▲1.2% | 165d ▲7.1% | 154d |
| Cash Conv. Cycle | 158d ▼9.7% | 175d ▲4.2% | 168d ▼8.7% | 184d ▲24.3% | 148d ▼1.3% | 150d ▼11.2% | 169d ▲19.0% | 142d ▲22.4% | 116d ▲63.4% | 71d |
| Working Capital Days | 3d ▼96.6% | 88d ▲25.7% | 70d ▲268.4% | 19d ▲416.7% | -6d ▲68.4% | -19d ▼290.0% | 10d ▼41.2% | 17d ▲150.0% | -34d ▼3300.0% | -1d |
| ROCE | 24.0% ▲9.1% | 22.0% ▲46.7% | 15.0% ▲15.4% | 13.0% ▼7.1% | 14.0% ▲27.3% | 11.0% ▼26.7% | 15.0% ▼16.7% | 18.0% ▲12.5% | 16.0% ▼42.9% | 28.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Zydus Lifesciences Limited
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Zydus Lifesciences Limited share price today?▾
Zydus Lifesciences Limited (ZYDUSLIFE) is currently trading at ₹1,090.5 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Zydus Lifesciences Limited available in F&O (Futures & Options)?▾
Yes, Zydus Lifesciences Limited (ZYDUSLIFE) is part of the NSE F&O segment with a lot size of 900 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Zydus Lifesciences Limited 52-week high and low?▾
Zydus Lifesciences Limited's 52-week high is ₹1,116 and the 52-week low is ₹836. The current price of ₹1,090.5 is 2.3% below the 52W high.
What is Zydus Lifesciences Limited P/E ratio?▾
Zydus Lifesciences Limited's current P/E ratio is 20. This indicates the market is paying ₹20 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Zydus Lifesciences Limited options?▾
Zydus Lifesciences Limited options are traded on NSE with monthly expiry contracts (lot size: 900 shares). To trade ZYDUSLIFE options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.